Questions to Ask Your Retina Specialist About Macular Degeneration Injections and Follow-Up

The waiting room has that particular hush of people whose pupils have just been dilated. A man in his seventies is squinting at a sheet of paper folded into quarters, the handwriting on it large and uneven. His daughter wrote it for him last night: three questions to ask the retina specialist, then a fourth added in a different pen. He will forget two of them the moment the doctor says the word “injection.”

That moment is common enough that it deserves a plan. Age-related macular degeneration, the slow wearing-down of the central part of the retina, is one of the most frequent reasons people over 60 end up in a retina clinic, and for the wet form, treatment usually means repeated injections into the eye over months or years. The appointment is long. The vocabulary is new. And the decisions that matter most, about schedules, scans and what to watch for, are easier to make when you know what to ask.

This explainer walks through what actually happens, what the evidence supports, and the questions worth bringing.

What to expect at a retina specialist appointment

A retina specialist is an ophthalmologist, a medical doctor trained in eye disease and surgery, who has completed extra fellowship training in disorders of the retina, the light-sensing tissue lining the back of the eye, and the vitreous, the clear gel that fills it. Most people are referred by an optometrist or general ophthalmologist after something looks wrong on a routine exam or after a change in central vision.

The visit is longer than an ordinary eye test. Dilating drops, which widen the pupil so the back of the eye can be examined and photographed, take time to work and leave vision blurry and light-sensitive for several hours afterward, according to the Mayo Clinic. That is why clinics ask you to bring sunglasses and someone to drive you home.

A few things make the time count. Bring a current list of every medicine and supplement you take, including over-the-counter products and eye drops. Note when you first noticed a change in vision, which eye, and whether it came on over days or months. Bring your glasses and any previous eye records or scans if you have them. If a family member has macular degeneration, say so; the National Eye Institute lists family history among the main risk factors, along with age and smoking.

Expect the appointment to move in stages: a vision check, drops, imaging, then the examination and conversation. If an injection is recommended, many clinics offer it the same day. You can ask for time to think; the choice is yours and the team’s together.

What tests will a retina specialist do?

The sequence is fairly standard, and knowing it reduces the sense of being passed from machine to machine. First comes a visual acuity test, reading letters on a chart, which gives a baseline number that will be repeated at every visit. You may also be shown an Amsler grid, a square of straight lines with a central dot, used to detect distortion or missing patches in central vision.

After dilation, the specialist examines the retina directly with a bright light and a hand-held lens. Then comes imaging. Optical coherence tomography, usually called OCT, is a painless scan that uses light waves to build cross-sectional pictures of the retina, fine enough to show fluid pockets, swelling and the thin layers beneath the macula. The Mayo Clinic describes OCT as the core tool both for diagnosing wet macular degeneration and for tracking how it responds to treatment.

Fluorescein angiography may be added when the picture is unclear. A yellow dye is injected into an arm vein, and a camera photographs it as it travels through the retinal vessels, revealing leaking or abnormal vessels. The dye can temporarily tint skin and urine and occasionally causes nausea; serious reactions are uncommon but the team will ask about allergies first. OCT angiography, a newer dye-free technique, maps blood flow using the OCT scanner itself. For the dry form, fundus autofluorescence, which photographs the natural glow of retinal pigment, helps measure areas of cell loss.

Useful questions here are simple: Which of these tests will I have today? Can you show me my scan and point to what you are seeing? Which test will you repeat at each follow-up?

How macular degeneration injections actually work

In the wet, or neovascular, form of macular degeneration, fragile new blood vessels grow beneath the macula, the small central region of the retina responsible for reading, faces and fine detail. These vessels leak fluid and blood, lifting and scarring the tissue above them. The growth is driven largely by a protein called vascular endothelial growth factor, or VEGF, which signals blood vessels to sprout and become leaky.

Anti-VEGF medicines are proteins designed to bind that signal and switch it off. Delivered into the vitreous gel, they reduce leakage and can shrink the abnormal vessels. The NHS describes them as the main treatment for wet AMD, aimed at stopping vision getting worse and, in some people, improving it. Several generic agents in this class exist; which one is used is a clinical decision for the prescribing team.

The injection itself takes seconds, though the preparation takes longer. Numbing drops or gel are applied, the eye surface and lids are cleaned with an antiseptic, and a small device holds the lids apart so you cannot blink. You are asked to look in a particular direction. The needle passes through the white of the eye, the sclera, a few millimeters from the edge of the colored iris, not through the pupil. Most people describe pressure rather than pain. Afterward the team may check eye pressure and confirm you can still see light or hand movements.

Because the medicine is gradually cleared from the eye, its effect fades over weeks, which is why treatment is repeated and why the schedule, not any single injection, is the real subject of your conversation with the specialist.

Who injections are usually for, and who is usually asked to wait

Anti-VEGF injections are intended for eyes with active wet macular degeneration: evidence of leaking vessels on OCT or angiography, often with recent change in vision. The same medicines are used for other retinal conditions such as diabetic macular edema and retinal vein occlusion, which is why you may hear them discussed in general terms, but in AMD the trigger for treatment is active neovascular disease.

Dry macular degeneration, the far more common form, does not respond to anti-VEGF medicines because there is no leakage to stop. People with early or intermediate dry AMD are usually monitored rather than injected. MedlinePlus notes that dry AMD can progress to the wet form, so monitoring is active rather than passive: regular scans and home checks are the plan, not an absence of one.

Geographic atrophy, the advanced stage of dry AMD in which patches of retinal cells have died, sits in a different category. Medicines in a class called complement inhibitors, which dampen part of the immune system implicated in cell loss, have been approved in some regions to slow the growth of these patches. The evidence shows slowed lesion growth on imaging; it has not shown improved vision, and the National Eye Institute frames these as options to discuss rather than a standard for everyone.

Some people with wet AMD are also asked to wait or pause. If an eye has long-standing scarring with no fluid, further injections may add little. If disease is quiet on scans over repeated visits, the team may extend intervals or trial a monitoring period. An active eye-surface infection usually means postponing that day’s injection. None of these judgments are made from a single number; they come from the pattern across your scans, your vision, and your own account of what you see.

Questions to ask your retina specialist about the diagnosis

Diagnosis questions come first because they shape everything after. Start with type: Is this dry or wet macular degeneration, and in which eye? The answer determines whether injections are even on the table. Then stage. Early, intermediate and advanced AMD are defined by the size and number of drusen, the yellowish deposits that build up under the retina, and by whether there is cell loss or new vessel growth. The National Eye Institute uses these stages, and your team should be able to tell you which applies.

Ask what the OCT shows. Is there fluid beneath the retina, within it, or under the pigment layer? Is there scar tissue already? Fluid can often be treated; scar generally cannot be reversed, and knowing the proportion of each sets honest expectations. Ask to see the image. Most clinics will turn the screen toward you, and a scan explained once is worth several pages of leaflet.

Ask about the other eye. The Johns Hopkins Medicine overview notes that when one eye has advanced disease, the fellow eye carries higher risk, which is why both eyes are scanned even when only one has symptoms.

Finally, ask what your vision measurement is today and how the team will track it. A baseline acuity line on the chart becomes the reference point for every later visit, and it tells you whether “stable” means holding where you are or something else. Write the answers down, or ask whether the clinic can print a summary.

Questions to ask your retina specialist about the injection plan

Once wet AMD is confirmed, the conversation shifts from what to how often, and this is where most of the confusion lives. Ask which approach the clinic uses. Three broad strategies exist: a fixed interval, where injections happen on a set timetable regardless of findings; as-needed treatment, where the eye is scanned regularly and injected only when fluid returns; and treat-and-extend, where the interval between injections is lengthened step by step while the retina stays dry and shortened if fluid reappears. The Mayo Clinic notes that injections may be needed every four to six weeks at first, so the early phase is intensive whichever strategy is chosen.

Ask what “stable” or “dry” means on your scan. For some teams it is zero fluid; for others, a small stable pocket that does not threaten vision is tolerated. Knowing the target helps you understand why an interval is extended or pulled back.

Ask how a missed appointment is handled, since fluid can return silently and a long gap can undo months of control. Ask whether both eyes, if both need treatment, are injected the same day or on separate visits, and how that affects your schedule. Ask whether the medicine might be switched over time and who decides that; switching is a team judgment based on response, never something to request from a brand name you read about.

Ask how long each visit typically takes, whether scans and injection happen together, and who you will see. Practical answers matter when a treatment runs for years, and a plan you can actually keep is the one most likely to protect your sight.

How follow-up schedules differ, and why it matters

The schedule is the treatment. The medicine wears off; the question is how the team detects that moment before vision is lost. Each strategy trades off visit burden against the risk of under-treatment, and the right one depends on how your eye behaves, how far you travel, and how reliably you can attend. The table summarizes the three approaches in neutral terms.

Approach	How it works	Visits and scans	Trade-offs to ask about
Fixed interval	Injection at every visit on a set timetable	Regular, predictable; scans confirm status	Simplest to plan; some eyes receive injections they might not have needed
As-needed (PRN)	Regular scans; injection only when fluid or activity returns	Frequent monitoring visits, fewer injections	Fewer injections but more scan-only visits; relies on catching recurrence promptly
Treat-and-extend	Injection at every visit; interval lengthened while dry, shortened if fluid returns	Visits spaced progressively further apart when disease is quiet	Fewer total visits over time; interval changes can feel unpredictable

Whatever the strategy, the early months are the most demanding. Imaging drives the decisions, so a visit without a scan is rare. Ask how the team will communicate a change in interval, what happens if you develop symptoms before your scheduled date, and whether the clinic has a way to bring you in early. The NHS stresses that treatment is ongoing rather than a one-off; the aim is a rhythm that keeps the retina dry with the fewest visits that safely achieve it, and that rhythm is set jointly, visit by visit.

What the days and weeks after an injection usually look like

The first few hours are the strangest. The antiseptic used to clean the eye leaves a gritty, sandy feeling that fades as the surface recovers; blinking a lot and resisting the urge to rub both help. Vision is blurred from dilation and from the drops, so reading or driving that evening is off. A small red patch on the white of the eye, a subconjunctival hemorrhage from the needle track, is common and harmless, and it fades on its own in the way a bruise does.

Many people notice new floaters, dark specks or threads drifting across vision, in the first day or two. Some are tiny air bubbles that rise and disappear; others are the medicine itself before it disperses. A few settled floaters are expected. A sudden shower of them, or flashes of light, is not, and belongs in the red-flag section below.

Over the following weeks, the effect on the retina happens quietly. Fluid seen on OCT often reduces before you notice any change in vision, which is why the next scan, not your own impression, usually guides the next step. If vision does improve, the gain tends to build over the first months of treatment rather than arriving overnight. The Mayo Clinic is clear that treatment can halt or slow further loss and, for some people, recover a portion of vision, but it does not restore sight already lost to scarring.

Follow-up usually coincides with the next injection or scan date set by your team. Keep a simple note of anything unusual between visits: a day of distortion, a new blind spot, a change in how one eye reads text. Those observations, matched to the scan, make the next decision better.

Risks, side effects and alternatives in plain terms

Intravitreal injection is one of the most frequently performed procedures in eye care, and its common effects are mild and short-lived: surface irritation, redness, floaters, a temporary rise in eye pressure that the team may check before you leave. Mild aching for a day is not unusual.

Serious complications are uncommon, and the NHS describes them as rare, but they are worth naming so you recognize them. Endophthalmitis is an infection inside the eye, usually declaring itself within days with increasing pain, worsening redness and falling vision; it is an emergency. Inflammation without infection can also occur and is treated differently. Retinal tear or detachment, where the retina pulls away from the wall of the eye, is rare and shows up as flashes, a curtain-like shadow or a burst of floaters. Accidental contact with the lens can hasten a cataract. A sustained rise in eye pressure is monitored at visits.

Because small amounts of anti-VEGF medicine enter the bloodstream, a theoretical question about cardiovascular risk has been studied; the evidence has not shown a clear increase, but people with a recent stroke or heart attack should mention it so the team can weigh it.

Alternatives are limited and depend on the subtype. Photodynamic therapy, in which a light-activated medicine is infused and then triggered by a laser aimed at the abnormal vessels, is now used mainly for particular variants or alongside injections. Thermal laser is reserved for rare cases where vessels sit away from the center. Observation is reasonable for inactive, scarred eyes. Low-vision rehabilitation, which teaches magnification, lighting and technique, is not an alternative to treatment but a complement that the National Eye Institute recommends at any stage. Ask which of these apply to your eye and why.

First signs of retina problems: what to report between visits

This is not a self-diagnosis list. Several conditions share these features, and only an examination sorts them out. It is a guide to what your team wants to hear about promptly, because in macular degeneration the gap between noticing something and being scanned is where vision can be lost.

The hallmark of macular trouble is distortion. Straight edges, such as door frames, tiles or lines of text, appear bent or wavy. Faces blur in the middle while the surroundings stay sharp. A gray, blank or dark patch sits in the center of vision in one eye. Colors look washed out, or you need noticeably more light to read than you did a few months ago. The Cleveland Clinic notes that early dry AMD may have no symptoms at all, which is why scans continue even when you feel fine.

The Amsler grid is the tool for catching change at home. Use it in good light, wearing your reading glasses, at your usual reading distance. Cover one eye, fix on the central dot, and notice whether any lines bend, blur or vanish. Then switch eyes. Doing it the same way each time makes small changes easier to spot. The Mayo Clinic suggests regular use for people with AMD, and your team will tell you how often.

Report any new distortion or blank area in either eye, even if your appointment is weeks away. The fellow eye matters as much as the treated one. Sudden flashes, a shower of floaters or a shadow spreading from the edge of vision point to a different, urgent retinal problem and need same-day contact.

Dry AMD and geographic atrophy: questions when injections are not the answer

Most people with macular degeneration have the dry form, and many of them leave the clinic without an injection and with a feeling that nothing is being done. Something is, and it helps to ask about it directly.

Ask whether you qualify for the AREDS2 formulation. In the Age-Related Eye Disease Studies run by the National Eye Institute, a specific combination of vitamins C and E, zinc, copper, lutein and zeaxanthin reduced the risk of progressing from intermediate to advanced AMD by about 25 percent over five years. The benefit was seen in intermediate AMD or advanced disease in one eye; it was not shown in early AMD, and these supplements have not been shown to prevent AMD in people without it. The second study replaced beta-carotene with lutein and zeaxanthin partly because beta-carotene raised lung cancer risk in smokers. Because supplements interact with other medicines and conditions, whether to take them is a decision for you and your team, not a shelf choice.

Ask about smoking. It is the strongest modifiable risk factor, and stopping is the single most useful lifestyle step at any stage, according to the NHS. Ask about diet, blood pressure and the role of ultraviolet protection, where the evidence is softer but the advice is low-risk.

If you have geographic atrophy, ask whether complement inhibitor injections are available where you are treated and what they have been shown to do. The honest answer, based on the trials that led to approval, is that they slow the enlargement of atrophy on imaging, with no demonstrated improvement in vision and with some increase in the risk of developing wet AMD in the treated eye. That trade-off is personal, and it deserves an unhurried conversation.

What people often get wrong about macular degeneration injections

Misunderstandings tend to cluster around the same few ideas, and each one has a cost.

“The needle goes into the pupil.” It does not. It passes through the white of the eye several millimeters from the cornea, into the gel behind the lens, while you look away from it. Most people never see it.

“It will be agonizing.” Numbing drops or gel are applied first. The commonest description afterward is pressure, then a scratchy surface from the antiseptic for a few hours.

“One injection will fix it.” The medicine is cleared from the eye over weeks. Control depends on repetition, which is why the schedule is the real decision. The NHS describes anti-VEGF treatment as ongoing.

“My vision is stable, so I can stop.” Fluid often returns before you notice any change, and the scan sees it first. Stopping or lengthening treatment is a team decision based on imaging, never a conclusion drawn from a good week.

“Macular degeneration means going completely blind.” It damages central vision. Peripheral vision, used for moving around a room or seeing shapes at the edge, is typically preserved, as MedlinePlus explains.

“Dry always turns wet.” It can, which is why monitoring matters, but many people with dry AMD never develop the wet form.

“Reading and screens wear the macula out.” There is no evidence that using your eyes damages them. Good light and magnification make life easier, nothing more.

“Supplements prevent it.” The AREDS2 formulation slowed progression in intermediate disease; it has not been shown to prevent AMD in healthy eyes, according to the National Eye Institute.

Questions to ask your care team: the list to bring

If you remember only five, make them these: What type and stage of macular degeneration do I have, and in which eye? What does my scan show, and can I see it? Which scheduling approach will we use and how will you decide to change it? What symptoms should make me call before my next visit? Who do I call, including outside clinic hours?

The longer list, grouped so you can hand it to the person who comes with you:

• Diagnosis: Is there fluid, scar, or both? How is my other eye? What is my vision measurement today?
• Treatment: Why injections for me, and why now? What do you hope treatment will achieve for this eye? What would make you consider a different approach or a switch of medicine?
• Schedule: How often at first, and how will the interval be adjusted? Will scans happen at every visit? What happens if I miss or need to move an appointment?
• Day of injection: How long will I be here? Can I eat and take my usual medicines? Do I need someone to drive me? When can I shower, read, work or exercise?
• Safety: Which side effects are expected and which are warning signs? Should my blood thinners or any other medicine be mentioned to anyone?
• Living with it: Am I safe to drive, and how will that be assessed? Can you refer me to low-vision rehabilitation? Should I use an Amsler grid, and how often?
• Dry AMD: Do I meet the criteria for the AREDS2 formulation? What else, besides stopping smoking, has evidence?

Ask for a written summary of the plan. The Johns Hopkins Medicine overview points out that AMD care stretches over years, and a plan you can reread beats one you half-remember from a dilated afternoon. Every answer here belongs to your treating team; your job is to make sure the questions get asked.

When to call your doctor

Most of the time after an injection, the eye settles within a day and the only task is to turn up to the next appointment. A small number of situations need a same-day call to the retina clinic, or emergency eye care if the clinic is closed. Do not wait for the next scheduled visit for any of the following.

• Eye pain that is increasing rather than easing, especially in the first week after an injection.
• Redness that is spreading or worsening, or new discharge from the eye.
• A drop in vision in the injected eye, or vision that was clearing and is now getting worse.
• New sensitivity to light that was not present after previous injections.
• A sudden shower of floaters, flashes of light, or a shadow or curtain moving across any part of vision in either eye.
• New distortion, a new blank or gray patch, or a sudden change on your Amsler grid in either eye between visits.
• Any symptom that frightens you and that you cannot explain.

The first three, together, are the pattern of endophthalmitis, the rare infection inside the eye that the NHS flags as a serious complication; it is treatable but only if seen quickly. Flashes, floaters and a curtain point toward retinal tear or detachment, which the Mayo Clinic treats as an emergency. New distortion in the untreated eye may mean the disease has become active there and benefits from early scanning.

Before you leave your first appointment, make sure you have the clinic’s daytime number, the out-of-hours route, and a clear idea of what the team considers urgent. That short conversation is one of the most protective things you can do, and the treating team will always rather hear from you than not.

Frequently asked questions

What are the top 5 questions to ask my eye doctor about macular degeneration?

Ask which type and stage you have and in which eye; what your scan shows and whether you can see it; which injection schedule the team uses and how it will change; which symptoms mean you should call before your next visit; and who to contact outside clinic hours. Those five cover diagnosis, plan and safety, and the answers set realistic expectations for a treatment that often continues for years.

What should I expect at my first retina specialist appointment?

Expect a longer visit than a routine eye test: a vision chart, dilating drops, imaging such as OCT and possibly dye angiography, then an examination and discussion. Dilation blurs vision and increases light sensitivity for several hours, so bring sunglasses and arrange a ride. If wet AMD is found, an injection may be offered the same day, though you can ask for time to decide.

What tests will a retina specialist do for macular degeneration?

The usual set is a visual acuity test, an Amsler grid check, a dilated retinal examination and optical coherence tomography, a painless light-based scan that shows retinal layers and fluid. If the picture is unclear, fluorescein angiography uses a dye injected into an arm vein to reveal leaking vessels. Fundus autofluorescence may be used to measure areas of cell loss in dry AMD. OCT is typically repeated at follow-up visits.

What are the first signs of retina problems I should report?

Report distortion, where straight lines look bent or wavy; a blurred, gray or blank patch in the center of vision in one eye; faded colors; or needing much more light to read. These need prompt review but are not a self-diagnosis. Sudden flashes, a shower of floaters or a spreading shadow suggest a different urgent problem and warrant same-day contact with eye care.

Do macular degeneration injections hurt?

Most people feel pressure rather than sharp pain. Numbing drops or gel are applied first, and the needle enters the white of the eye while you look away. The commonest aftereffect is a gritty, scratchy sensation from the antiseptic for a few hours, sometimes with mild aching for a day. Pain that increases over the following days is not expected and should be reported to the clinic the same day.

How often will I need injections and follow-up?

Early in treatment, injections may be needed every four to six weeks, according to the Mayo Clinic, with scans at most visits. After that, the interval depends on the approach your team uses: fixed, as-needed or treat-and-extend, where the gap is lengthened while the retina stays dry. Decisions are based on OCT findings rather than on how your vision feels, and your team sets each interval.

Can I drive home after a retina injection?

Not on the day. Dilating drops blur vision and increase glare for several hours, and the injected eye is often watery and irritated, so clinics ask you to arrange transport. Whether you are safe to drive in general depends on your vision in both eyes and local legal standards; ask your retina specialist how that is assessed and whether your current acuity meets the requirement.

What happens if I miss an injection appointment?

Fluid can return without symptoms, so a long gap risks losing ground that treatment had gained. Contact the clinic as soon as you know you will miss a date so it can be rebooked promptly, and ask at your first visit how missed appointments are handled. Any change in vision or new distortion during the gap should prompt a same-day call rather than waiting for the rescheduled visit.

Can dry macular degeneration turn into wet, and should I keep having scans?

Yes, dry AMD can progress to the wet form, which is why monitoring continues even when vision feels unchanged, as MedlinePlus explains. Many people with dry AMD never develop wet disease. Regular imaging and home Amsler grid checks aim to catch any change early, when anti-VEGF injections work best. Ask your team how often you should be scanned and what should trigger an earlier visit.

Are vitamin supplements useful for macular degeneration?

For intermediate AMD, or advanced AMD in one eye, the National Eye Institute’s AREDS2 formulation reduced progression to advanced disease by about 25 percent over five years. It has not been shown to help early AMD or to prevent the condition in healthy eyes. Because supplements can interact with medicines and conditions, including smoking history, whether to take them is a decision to make with your treating team.

References

• National Eye Institute (NIH): Age-Related Macular Degeneration
• National Eye Institute (NIH): Age-Related Eye Disease Studies (AREDS/AREDS2)
• MedlinePlus: Macular Degeneration
• Cleveland Clinic: Macular Degeneration

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.